Dotamtate Pb-212

ITM-11, a targeted radiopharmaceutical, significantly improved progression-free survival (PFS) in patients with Grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Molecular Partners' Radio-DARPin MP0712, targeting DLL3, is set to begin first-in-human trials in 2025, marking a key advancement in targeted cancer therapy.

Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.

Orano Med has commenced construction of a $265 million Advanced Thorium Extraction Facility to supply lead-212 for alpha therapy cancer treatments.

Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.